Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis

Bibliography

• GABRIEL SE, CROWSON CS, KREMERS HM et al.: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. (2003) 48:54–58.
   PubMed Web of Science ®Google Scholar
• GABRIEL SE: The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. N Am. (2001) 27:269–281.
   PubMed Web of Science ®Google Scholar
• HOCHBERG MC, SPECTOR TD: Epidemiology of rheumatoid arthritis: update. Epidemiol. Rev. (1990) 12:247–252.
   PubMed Web of Science ®Google Scholar
• CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl. J. Med. (2001) 344:907–916.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview describing cytokinepathways in RA.
   Google Scholar
• EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl. J. Med. (2004) 350:2572–2581.
   PubMed Web of Science ®Google Scholar
• •Controlled randomised trial describing the effects of depleting B cells in patients with RA.
   Google Scholar
• TAK PP, BRESNIHAN B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. (2000) 43:2619–2633.
   PubMed Web of Science ®Google Scholar
• KONTTINEN YT, AINOLA M, VALLEALA H et al.: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58:691–697.
   PubMed Web of Science ®Google Scholar
• KINNE RW, BRAUER R, STUHLMULLER B, PALOMBO-KINNE E, BURMESTER GR: Macrophages in rheumatoid arthritis. Arthritis. Res. (2000) 2:189–202.
   PubMedGoogle Scholar
• BRINCKERHOFF CE: Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum. (1991) 34:1073–1075.
   PubMed Web of Science ®Google Scholar
• BUTCHER EC: Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell (1991) 67: 1033–1036.
   Google Scholar
• ••A review providing a clear overview of the different steps in leukocyte migration.
   Google Scholar
• SPRINGER TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 76:301–314.
   PubMed Web of Science ®Google Scholar
• O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N Engl. J. Med. (2004) 350:2591–2602.
   PubMed Web of Science ®Google Scholar
• ••Recent paper reviewing past and currenttherapeutic strategies in the treatment of RA.
   Google Scholar
• SCOTT DL: Pursuit of optimal outcomes in rheumatoid arthritis. Pharmacoeconomics (2004) 22:13–26.
   PubMedGoogle Scholar
• DROSSAERS-BAKKER KW, ZWINDERMAN AH, VLIELAND TP et al.: Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum. (2002) 47:383–390.
   PubMed Web of Science ®Google Scholar
• SHARP JT, WOLFE F, LASSERE M et al.: Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers. Rheumatol (2004) 31:1062–1072.
   Web of Science ®Google Scholar
• MCQUEEN FM, STEWART N, CRABBE J et al.: Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann. Rheum. Dis. (1998) 57:350–356.
   PubMed Web of Science ®Google Scholar
• MCGONAGLE D, CONAGHAN PG, O'CONNOR P et al.: The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum. (1999) 42:1706–1711.
   PubMed Web of Science ®Google Scholar
• STRAND V COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. (1999) 159:2542–2550.
   PubMed Web of Science ®Google Scholar
• KORPELA M, LAASONEN L, HANNONEN P et al.: Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. (2004) 50:2072–2081.
   PubMed Web of Science ®Google Scholar
• •Study showing inhibition of joint damage after early treatment with DMARDs.
   Google Scholar
• O'DELL JR, LEFF R, PAULSEN G et al.: Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:1164–1170.
   PubMed Web of Science ®Google Scholar
• BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 350:309–318.
   PubMed Web of Science ®Google Scholar
• •COBRA study showing the benefits of early aggressive treatment of RA.
   Google Scholar
• LANDEWE RB, BOERS M, VERHOEVEN AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. (2002) 46:347–356.
   PubMed Web of Science ®Google Scholar
• WOLFE F, HAWLEY DJ: The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J. Rheumatol (1998) 25:2108–2117.
   PubMed Web of Science ®Google Scholar
• COHEN S, CANNON GW, SCHIFF M et al.: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment ofRheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. (2001) 44:1984–1992.
   PubMed Web of Science ®Google Scholar
• OLSEN NJ, STEIN CM: New drugs for rheumatoid arthritis. N Engl. J. Med. (2004) 350:2167–2179.
   PubMed Web of Science ®Google Scholar
• LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl. J. Med. (2000) 343:1594–1602.
   PubMed Web of Science ®Google Scholar
• ••Large controlled randomised trial provingthe efficacy of targeted therapies in RA.
   Google Scholar
• DAY R: Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet (2002) 359:540–541.
   PubMed Web of Science ®Google Scholar
• BRESNIHAN B, CUNNANE G: Infection complications associated with the use of biologic agents. Rheum. Dis. Clin. N Am. (2003) 29:185–202.
   PubMed Web of Science ®Google Scholar
• BUTCHER EC, PICKER LJ: Lymphocyte homing and homeostasis. Science (1996) 272:60–66.
   PubMed Web of Science ®Google Scholar
• CARLOS TM, HARLAN JM: Leukocyte-endothelial adhesion molecules. Blood (1994) 84:2068–2101.
   PubMed Web of Science ®Google Scholar
• HASKARD DO: Cell adhesion molecules in rheumatoid arthritis. Curr. Opin. Rheumatol (1995) 7:229–234.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, FUJII K, HUBSCHER S et al.: Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. Arthritis Rheum. (1998) 41:1365–1377.
   PubMed Web of Science ®Google Scholar
• SZEKANECZ Z, KOCH AE: Cell-cell interactions in synovitis. Endothelial cells and immune cell migration. Arthritis Res. (2000) 2:368–373.
   PubMedGoogle Scholar
• •Excellent overview of the interactions between leukocytes and endothelial cells in RA.
   Google Scholar
• SZEKANECZ Z, KOCH AE: Update on synovitis. Curr. Rheumatol Rep. (2001) 3:53–63.
   PubMedGoogle Scholar
• MARSHALL D, HASKARD DO: Clinical overview of leukocyte adhesion and migration: where are we now? Semin. Immunol (2002) 14:133–140.
   Web of Science ®Google Scholar
• TAK PP, THURKOW EW, DAHA MR et al.: Expression of adhesion molecules in early rheumatoid synovial tissue. Clin. Immunol Immunopathol (1995) 77:236–242.
   PubMedGoogle Scholar
• •Study describing the expression of a variety of adhesion molecules in synovial tissue of patients with early RA.
   Google Scholar
• KRAAN MC, SMITH MD, WEEDON H et al.: Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann. Rheum. Dis. (2001) 60:296–298.
   PubMed Web of Science ®Google Scholar
• SMITH MD, SLAVOTINEK J, AU V et al.: Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. Rheumatology (2001) 40:965–977.
   PubMed Web of Science ®Google Scholar
• DOLHAIN RJ, TAK PP, DIJKMANS BA et al.: Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br. J. Rheumatol (1998) 37:502–508.
   PubMedGoogle Scholar
• TAK PP, TAYLOR PC, BREEDVELD FC et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. [see comments]. Arthritis Rheum. (1996) 39:1077–1081.
   PubMed Web of Science ®Google Scholar
• •Study showing decreased expression of adhesion molecules in RA synovial tissue after anti-TNF-a treatment.
   Google Scholar
• YOUSSEF PP, TRIANTAFILLOU S, PARKER A et al.: Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum. (1996) 39:1970–1979.
   PubMed Web of Science ®Google Scholar
• PALEOLOG EM, HUNT M, ELLIOTT MJ et al.: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. (1996) 39:1082–1091.
   PubMed Web of Science ®Google Scholar
• SUMARIWALLA PF, MALFAIT AM, FELDMANN M: P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor. Clin. Exp. Immunol (2004) 136:67–75.
   PubMed Web of Science ®Google Scholar
• BHUSHAN M, BLEIKER TO, BALLSDON AE et al.: Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol (2002) 146:824–831.
   PubMed Web of Science ®Google Scholar
• ALBELDA SM, BUCK CA: Integrins and other cell adhesion molecules. FASEB J. (1990) 4:2868–2880.
   PubMed Web of Science ®Google Scholar
• JACKSON DY : Alpha 4 integrin antagonists. Curr. Pharm. Des. (2002) 8:1229–1253.
   Google Scholar
• STORGARD CM, STUPACK DG, JONCZYK A et al.: Decreased angiogenesis and arthritic disease in rabbits treated with an av133 antagonist. J. Clin. Invest. (1999) 103:47–54.
   PubMed Web of Science ®Google Scholar
• GERLAG DM, BORGES E, TAK PP et al.:Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res. (2001) 3:357–361.
   PubMedGoogle Scholar
• BADGER AM, BLAKE S, KAPADIA R et al.: Disease-modifying activity of SB 273005, an orally active, nonpeptide avl33 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. (2001) 44:128–137.
   PubMed Web of Science ®Google Scholar
• MedImmune initiates Phase I/II clinical study with Vitaxin. Expert. Rev. Anti-Cancer Ther. (2001) 1:166.
   Google Scholar
• WILDER RL: Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. (2002) 61\(Suppl. 2):ii96-ii99.
   Google Scholar
• KAVANAUGH AF, DAVIS LS, JAIN RI et al.: A Phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol (1996) 23:1338–1344.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, BLACKBURN WD Jr, TAMI JA, SHANAHAN WR: A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. J. Rheumatol (2002) 29:447–453.
   PubMed Web of Science ®Google Scholar
• KRAAN MC, VAN KUIJK AW, DINANT HJ et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. (2002) 46:2776–2784.
   PubMed Web of Science ®Google Scholar
• •Open-label study showing the effects of an LFA-3-IgG1 fusion protein on synovial inflammation in patients with psoriatic arthritis.
   Google Scholar
• GOEDKOOP AY, DE RIE MA, PICAVET DI et al.: Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch. Dermatol Res. (2004) 295:465–473.
   PubMed Web of Science ®Google Scholar
• ELLIS CN, KRUEGER GG: Treatment ofchronic plaque psoriasis by selective targeting of memory effectorT lymphocytes. N Engl J. Med. (2001) 345:248–255.
   PubMed Web of Science ®Google Scholar
• IUIS/WHO SUBCOMMITTEE ON CHEMOKINE NOMENCLATURE: Chemokine/chemokine receptor nomenclature. J. Immunol Methods (2002) 262:1–3.
   PubMed Web of Science ®Google Scholar
• CYSTER JG: Chemokines and cell migration in secondary lymphoid organs. Science (1999) 286:2098–2102.
   PubMed Web of Science ®Google Scholar
• LUSTER AD: Chemokines-chemotactic gtokines that mediate inflammation. N Engl. J. Med. (1998) 338:436–445.
   PubMed Web of Science ®Google Scholar
• ••Extensive review on the impact ofchemokines on inflammatory processes.
   Google Scholar
• HARINGMAN JJ, LUDIKHUIZE J, TAK PP: Chemokines in joint disease: the key to inflammation? Ann. Rheum. Dis. (2004) 63:1186–1194.
   PubMed Web of Science ®Google Scholar
• MACKAY CR: Chemokines : immunology's high impact factors. Nat. ImmunoL (2001) 2:95–101.
   PubMed Web of Science ®Google Scholar
• BODOLAY E, KOCH AE, KIM J, SZEGEDI G, SZEKANECZ Z: Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J. Cell MoL Med. (2002) 6:357–376.
   PubMed Web of Science ®Google Scholar
• HOSAKA S, AKAHOSHI T, WADA C, KONDO H: Expression of the chemokine superfamily in rheumatoid arthritis. Clin. Exp. Immunol (1994) 97:451–457.
   PubMed Web of Science ®Google Scholar
• KOCH AE, KUNKEL SL, BURROWS JC et al.: Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. Immunol (1991) 147:2187–2195.
   Web of Science ®Google Scholar
• VILLIGER PM, TERKELTAUB R, LOTZ M: Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. Immunol (1992) 149:722–727.
   Web of Science ®Google Scholar
• RANDOLPH GJ, FURIE MB: A solublegradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J. Immunol (1995) 155:3610–3618.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC: Abandoned therapies andunpublished trials in rheumatoid arthritis. Curr. Opin. Rheumatol (2003) 15:253–258.
   PubMed Web of Science ®Google Scholar
• HARINGMAN JJ, TAK PP: Chemokine blockade: a new era in the treatment of rheumatoid arthritis. Arthritis Res. Ther. (2004) 6:93–97.
   PubMed Web of Science ®Google Scholar
• OGATA H, TAKEYA M, YOSHIMURAT, TAKAGI K, TAKAHASHI K: The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol (1997) 182:106–114.
   PubMed Web of Science ®Google Scholar
• GONG JH, UGUCCIONI M, DEWALD B, BAGGIOLINI M, CLARK-LEWIS I: RANTES and MCP-3 antagonists bind multiple chemokine receptors. J. Biol. Chem. (1996) 271:10521–10527.
   PubMed Web of Science ®Google Scholar
• GONG JH, RATKAY LG, WATERFIELD JD, CLARK-LEWIS I: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-Ipr mouse model./ Exp. Med. (1997)
   PubMedGoogle Scholar
• BORZI RM, MAZZETTI I, CATTINI L et al.: Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines. Arthritis Rheum. (2000) 43:1734–1741.
   PubMed Web of Science ®Google Scholar
• HARINGMAN JJ, SMEETS TJM, REINDERS-BLANKERT P, TAK PP: Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of rheumatoid arthritis, osteoarthritis and reactive arthritis patients. Arthritis Rheum. (2004) 50(Suppl.):87.
   Google Scholar
• HARINGMAN JJ, GERLAG DM, ZWINDERMAN AH et al.: Synovial tissue macrophages: highly sensitive biomarkers for response to treatment in rheumatoid arthritis patients. Ann. Rheum. Dis. (2004). Dec 2; epub ahead of print.Identification of synovial sublining macrophages as a sensitive biomarker for effective treatment in RA.
   Google Scholar
• LUSTER AD: Chemokines-chemotactic cytokines that mediate inflammation. N Engl. J. Med. (1998) 338:436–445.
   PubMed Web of Science ®Google Scholar
• BARNES DA, TSE J, KAUFHOLD M et al.: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. Clin. Invest. (1998) 101:2910–2919.
   Google Scholar
• STANFORD MM, ISSEKUTZ TB: The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. J. Leukoc. Biol. (2003) 74:791–799.
   PubMed Web of Science ®Google Scholar
• BRADFIELD PF, AMFT N, VERNON-WILSON E et al.: Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4* and CD8* T cell migration within synovial tissue. Arthritis Rheum. (2003) 48:2472–2482.
   PubMed Web of Science ®Google Scholar
• PABLOS JL, SANTIAGO B, GALINDO M et al.: Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J. Immunol (2003) 170:2147–2152.
   PubMed Web of Science ®Google Scholar
• SALOMON I, NETZER N, WILDBAUM G et al.: Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol (2002) 169:2685–2693.
   PubMed Web of Science ®Google Scholar
• HARINGMAN JJ, KRAAN MC, SMEETS TJ, ZWINDERMAN KH, TAK PP: Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62:715–721.
   PubMed Web of Science ®Google Scholar
• ••First human trial describing the effects of specific chemokine receptor (CCR1) blockade in patients with chronic inflammatory disease.
   Google Scholar
• KATSCHKE KJ JR, ROTTMAN JB, RUTH JH et al.: Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. (2001) 44:1022–1032.
   PubMed Web of Science ®Google Scholar
• GLADUE RP, TYLASKA LA, BRISSETTE WH et al.: CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. (2003) 278:40473–40480.
   PubMed Web of Science ®Google Scholar
• LOETSCHER P, UGUCCIONI M, BORDOLI L et al.: CCR5 is characteristic of Thl lymphocytes. Nature (1998) 391:344–345.
   PubMed Web of Science ®Google Scholar
• ZAPICO I, COTO E, RODRIGUEZ A et al.: CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. (2000) 1:288–289.
   PubMed Web of Science ®Google Scholar
• GARRED P, MADSEN HO, PETERSEN J et al.: CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumatol. (1998) 25:1462–1465.
   PubMed Web of Science ®Google Scholar
• YANG YF, MUKAI T, GAO P et al.: A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur. j Immunol (2002) 32:2124–2132.
   PubMed Web of Science ®Google Scholar
• GAO P, ZHOU XY, YASHIRO-OHTANI Y et al.: The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Thl chemokine receptors CCR5 and CXCR3. j Leukoc. Biol (2003) 73:273–280.
   PubMed Web of Science ®Google Scholar
• BRUHL H, CIHAK J, SCHNEIDER MA et al.: Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2* T cells. J. Immunol. (2004) 172:890–898.
   PubMed Web of Science ®Google Scholar
• QUINONES MP, AHUJA SK, JIMENEZ F et al.: Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. Clin. Invest. (2004) 113:856–866.
   Google Scholar
• FIFE BT, HUFFNAGLE GB, KUZIEL WA, KARPUS WJ: CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. (2000) 192:899–905.
   PubMed Web of Science ®Google Scholar
• BORING L, GOSLING J, CLEARY M, CFIARO IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 394:894–897.
   PubMed Web of Science ®Google Scholar
• BELPERIO JA, KEANE MP, BURDICK MD et al.: Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J. Clin. Invest. (2001) 108:547–556.
   PubMed Web of Science ®Google Scholar
• BIRD JE, GIANCARLI MR, KURIHARA T et al.: Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney. Int. (2000) 57:129–136.
   PubMed Web of Science ®Google Scholar
• BLEASE K, MEHRAD B, STANDIFORD TJ et al.: Enhanced pulmonary allergic responses to Asp ergillus in CCR2-/- mice. J. Immunol (2000) 165:2603–2611.
   PubMed Web of Science ®Google Scholar
• HOGABOAM CM, BONE-LARSON CL, STEINHAUSER ML et al.: Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. Am. J. Pathol (2000) 156:1245–1252.
   PubMed Web of Science ®Google Scholar
• QIN S, ROTTMAN JB, MYERS P et al.:The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. (1998) 101:746–754.
   PubMed Web of Science ®Google Scholar
• PATEL DD, ZACHARIAH JP, WHICHARD LP: CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin. Immunol (2001) 98:39–45.
   PubMed Web of Science ®Google Scholar
• RABIN RL, ALSTO N Mk SIRCUS JC et al.: CXCR3 is induced early on the pathway of CD4* T cell differentiation and bridges central and peripheral functions. J. Immunol. (2003) 171:2812–2824.
   PubMed Web of Science ®Google Scholar
• TAKEMURA S, BRAUN A. CROWSON G et al.: Lymphoid neogenesis in rheumatoid synovitis. J. Immunol (2001) 167:1072–1080.
   PubMed Web of Science ®Google Scholar
• AEBERLI D, SEITZ M, JUNI P, VILLIGER PM: Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-a inhibitors. Rheumatology (2005) 44:172–175.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC, PETERS AM, PALEOLOG E et al.: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. (2000) 43:38–47.
   PubMed Web of Science ®Google Scholar
• SMEETS TJ, KRAAN MC, VAN LOON ME, TAK PP: Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. (2003) 48:2155–2162.
   PubMed Web of Science ®Google Scholar
• GARCIA-VICUNA R, GOMEZ-GAVIRO MV DOMINGUEZ-LUIS MJ et al.: CC and OCC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. (2004) 50:3866–3877.
   PubMed Web of Science ®Google Scholar
• FOR THE AMD1300 HIV STUDY GROUP: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective cxcr4 receptor inhibitor, in HIV-1 infection. Acquir. Immune Defic. Syndr. (2004) 37:1253–1262.
   PubMed Web of Science ®Google Scholar
• LIANG M, ROSSER M, NG HP et al.: Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur. j Pharmacol. (2000) 389:41–49.
   PubMed Web of Science ®Google Scholar
• LIU ET, KARUTURI KR: Microarrays and clinical investigations. N Engl. J. Med. (2004) 350:1595–1597.
   PubMed Web of Science ®Google Scholar
• GERLAG DM, HARINGMAN JJ, SMEETS TJ et al.: Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum. (2004) 50:3783–3791.
   PubMed Web of Science ®Google Scholar
• CUNNANE G, MADIGAN k MURPHY E, FITZGERALD O, BRESNIHAN B: The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (2001) 40:62–69.
   PubMed Web of Science ®Google Scholar
• KRAAN MC, REECE RJ, BARG EC et al.: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. (2000) 43:1820–1830.
   PubMed Web of Science ®Google Scholar
• KATRIB A, SMITH MD, AHERN MJ et al.: Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remission. J. Rheumatol (2003) 30:10–21.
   PubMed Web of Science ®Google Scholar
• HARINGMAN JJ, GERLAG DM, SMEETS TJ et al.: A randomized controlled trial with an anti-CCL2 (MCP-1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. (2004) 50:S238.
   Google Scholar
• XANTHOU G, DUCHESNES CE, -WILLIAMS TJ, PEASE JE: CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur. j Immunol (2003) 33:2241–2250.
   PubMed Web of Science ®Google Scholar
• OVERALL CM, MCQUIBBAN GA, CLARK-LEWIS I: Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol. Chem. (2002) 383:1059–1066.
   PubMed Web of Science ®Google Scholar
• CARTER PH: Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr. Opin. Chem. Biol. (2002) 6:510–525.
   PubMed Web of Science ®Google Scholar